Source: ALL
Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs727502862
rs727502862
GPATCH8
0.010 GeneticVariation BEFREE ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia. 21594610

2011
dbSNP: rs753397550
rs753397550
COL1A2
0.010 GeneticVariation BEFREE ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia. 21594610

2011
dbSNP: rs1025993235
rs1025993235
PRPSAP2
0.010 GeneticVariation BEFREE ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia. 21594610

2011
dbSNP: rs1209613132
rs1209613132
COL1A2
0.010 GeneticVariation BEFREE ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia. 21594610

2011
dbSNP: rs1230053514
rs1230053514
SLC22A12
0.010 GeneticVariation BEFREE ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia. 21594610

2011
dbSNP: rs189660050
rs189660050
ZPBP2
0.010 GeneticVariation BEFREE ZPBP2 p.T69I was at the non-conserved region and was predicted to be benign by in silico analysis, whereas GPATCH8 p.A979P was at a highly conserved region and was predicted to be deleterious, which made p.A979P a conceivable candidate for juvenile-onset hyperuricemia. 21594610

2011
dbSNP: rs2231142
rs2231142
ABCG2
T 0.800 GeneticVariation GWASCAT Whereas the rs2231142 in ABCG2 gene had significant associations between gout and controls, between gout and hyperuricemia, and between hyperuricemia and controls (all p-values < 10<sup>-7</sup>), and the ORs were 4.34, 3.37 and 2.15 (all p-values < 0.001) after adjustment of potential confounders, respectively. 29453348

2018
dbSNP: rs2231142
rs2231142
ABCG2
0.800 GeneticVariation BEFREE Whereas the rs2231142 in ABCG2 gene had significant associations between gout and controls, between gout and hyperuricemia, and between hyperuricemia and controls (all p-values < 10<sup>-7</sup>), and the ORs were 4.34, 3.37 and 2.15 (all p-values < 0.001) after adjustment of potential confounders, respectively. 29453348

2018
dbSNP: rs33972313
rs33972313
SLC23A1
0.010 GeneticVariation BEFREE We measured plasma urate and genotyped for the SLC23A1 rs33972313 vitamin C variant in 106 147 individuals from the Copenhagen General Population Study, of which 24 099 had hyperuricaemia. 29939348

2018
dbSNP: rs2054576
rs2054576
ABCG2
0.010 GeneticVariation BEFREE We identified a hyperuricemia susceptible loci (rs2054576 in ABCG2, OR, 1.883; P = 4.7 × 10⁻⁸) that passed a genome-wide significance threshold, adjusted by clinical variables (male, age, BMI, current alcohol, and creatinine). 28776340

2017
dbSNP: rs1217691063
rs1217691063
MTHFR
0.030 GeneticVariation BEFREE We hypothesized that hyperuricemia would be associated with methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase (TS) 28-bp tandem repeat polymorphism. 19917450

2009
dbSNP: rs7903456
rs7903456
SHLD2
0.010 GeneticVariation BEFREE We have identified rs7903456 to be associated with hyperuricemia and uric acid level. 29942023

2018
dbSNP: rs28934583
rs28934583
UMOD
0.010 GeneticVariation BEFREE We describe here a novel heterozygous mutation of <i>UMOD</i> (c.249C>G; p.Cys83Trp) in an affected 9-year-old boy with progressive renal impairment and hyperuricemia. 29424336

2019
dbSNP: rs1137070
rs1137070
MAOA
0.010 GeneticVariation BEFREE We also found that MAOA enzyme activity by rs1137070 allele was associated with hyperuricemia and gout (P for trend = 1.53 x 10(-6) vs. wild-type allele). 19915868

2010
dbSNP: rs1232898090
rs1232898090
PPARA
0.010 GeneticVariation BEFREE Unadjusted and adjusted multiple logistic regressions showed that the odds ratios (OR) for hyperuricemia were not associated with Pro12Ala polymorphism in PPAR-γ2. 21968942

2012
dbSNP: rs4684846
rs4684846
PPARG
0.010 GeneticVariation BEFREE Three tag-single nucleotide polymorphisms, rs2292101, rs4684846, and rs1822825, of the PPARγ gene were selected to explore their association with hyperuricemia. 23237621

2013
dbSNP: rs2231142
rs2231142
ABCG2
0.800 GeneticVariation BEFREE Three SNPs, URAT1 rs11231825, GLUT9 rs16890979 and ABCG2 rs2231142, previously associated in our population with hyperuricemia and gout, were analyzed in 27 patients with HPRT deficiency treated with allopurinol for at least 5 years. 29879316

2018
dbSNP: rs16890979
rs16890979
SLC2A9
0.010 GeneticVariation BEFREE Three SNPs, URAT1 rs11231825, GLUT9 rs16890979 and ABCG2 rs2231142, previously associated in our population with hyperuricemia and gout, were analyzed in 27 patients with HPRT deficiency treated with allopurinol for at least 5 years. 29879316

2018
dbSNP: rs11231825
rs11231825
SLC22A12
0.010 GeneticVariation BEFREE Three SNPs, URAT1 rs11231825, GLUT9 rs16890979 and ABCG2 rs2231142, previously associated in our population with hyperuricemia and gout, were analyzed in 27 patients with HPRT deficiency treated with allopurinol for at least 5 years. 29879316

2018
dbSNP: rs7932775
rs7932775
SLC22A12
0.010 GeneticVariation BEFREE These SNPs had a joint additive effect of risk of HUA, with those individuals carrying at least one 'A' allele at the intron 3 SNP and two 'C' alleles at rs7932775 having a 5.88-fold (95% CI 1.25 to 15.57) increased risk of HUA in comparison to those with no risk alleles. 19833602

2010
dbSNP: rs121907892
rs121907892
SLC22A12
0.010 GeneticVariation BEFREE The strongest association with hyperuricaemia was observed for rs75786299 (IVS3+11A/G) with an OR of 32.05. rs7929627 (IVS7-103A/G) and rs3825017 (N82N) showed an association with hyperuricaemia with ORs of 2.56 and 2.29, respectively. rs11602903 (788A/T) and rs121907892 (W258X) were negatively correlated with hyperuricaemia with ORs of 0.350 and 0.447, respectively. 26603249

2015
dbSNP: rs11602903
rs11602903
SLC22A12
0.010 GeneticVariation BEFREE The strongest association with hyperuricaemia was observed for rs75786299 (IVS3+11A/G) with an OR of 32.05. rs7929627 (IVS7-103A/G) and rs3825017 (N82N) showed an association with hyperuricaemia with ORs of 2.56 and 2.29, respectively. rs11602903 (788A/T) and rs121907892 (W258X) were negatively correlated with hyperuricaemia with ORs of 0.350 and 0.447, respectively. 26603249

2015
dbSNP: rs2231142
rs2231142
ABCG2
0.800 GeneticVariation BEFREE The strongest association was detected at SLC22A12 rs505802 for uric acid (p=2.4×10(-50)) and ABCG2 rs2231142 for hyperuricemia (p3.6×10(-10)). 23238572

2013
dbSNP: rs505802
rs505802
SLC22A12
0.010 GeneticVariation BEFREE The strongest association was detected at SLC22A12 rs505802 for uric acid (p=2.4×10(-50)) and ABCG2 rs2231142 for hyperuricemia (p3.6×10(-10)). 23238572

2013
dbSNP: rs6855911
rs6855911
SLC2A9
0.010 GeneticVariation BEFREE The polymorphism rs6855911 in SLC2A9 may be a genetic marker to assess risk of hyperuricemia among Chinese male Han population. 20972595

2011